• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sientra Inc. (Amendment)

    12/12/22 4:18:19 PM ET
    $SIEN
    Industrial Specialties
    Health Care
    Get the next $SIEN alert in real time by email
    SC 13G/A 1 Sientra.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Sientra, Inc. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 82621J105 ----------------------------------------------------- (CUSIP Number) November 30, 2022 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.82621J105 13G Page 2 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 351 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 398,938 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 398,938 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 0.4% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.82621J105 13G Page 3 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley & Co. LLC I.R.S. # 13-2655998 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 0 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 0 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 0 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 0.0% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: BD, CO -------------------------------------------------------------------------------- CUSIP No.82621J105 13G Page 4 of 8 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: Sientra, Inc. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 420 SOUTH FAIRVIEW AVENUE SUITE 200 SANTA BARBARA CA 93117 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley (2) Morgan Stanley & Co. LLC -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway New York, NY 10036 (2) 1585 Broadway New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. (2) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Common Stock -------------------------------------------------------------- (e) CUSIP Number: 82621J105 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [x] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.82621J105 13G Page 5 of 8 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of November 30, 2022.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. (1) As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities. (2) As of the date hereof, Morgan Stanley & Co. LLC has ceased to be the beneficial owner of more than five percent of the class of securities. Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit 99.2 Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.82621J105 13G Page 6 of 8 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: December 12, 2022 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY Date: December 12, 2022 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley & Co. LLC -------------------------------------------------------------------- Morgan Stanley & Co. LLC EXHIBIT NO. EXHIBITS PAGE ----------- ---------- ---- 99.1 Joint Filing Agreement 7 99.2 Item 7 Information 8 * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.82621J105 13G Page 7 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT --------------------------------------------------- December 12, 2022 --------------------------------------------------- MORGAN STANLEY and Morgan Stanley & Co. LLC hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley Morgan Stanley & Co. LLC BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley & Co. LLC * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.82621J105 13G Page 8 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.2 ------------------ ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley & Co. LLC, a wholly-owned subsidiary of Morgan Stanley.
    Get the next $SIEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SIEN

    DatePrice TargetRatingAnalyst
    4/14/2022$8.00Buy
    Lake Street
    More analyst ratings

    $SIEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sientra Inc. (Amendment)

      SC 13G/A - Sientra, Inc. (0001551693) (Subject)

      2/20/24 1:38:37 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/6/24 10:00:53 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/15/23 3:19:14 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Sientra with a new price target

      Lake Street initiated coverage of Sientra with a rating of Buy and set a new price target of $8.00

      4/14/22 9:15:44 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Canaccord Genuity reiterated coverage on Sientra with a new price target

      Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $10.00 from $9.00 previously

      5/12/21 11:21:33 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SVB Leerink reiterated coverage on Sientra with a new price target

      SVB Leerink reiterated coverage of Sientra with a rating of Outperform and set a new price target of $11.00 from $10.00 previously

      5/12/21 7:20:27 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Menezes Ronald covered exercise/tax liability with 3,625 shares, decreasing direct ownership by 18% to 16,775 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:38 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Van Hove Caroline F. covered exercise/tax liability with 741 shares, decreasing direct ownership by 8% to 8,239 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:11 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form 4: Bennett Oliver Christian was granted 2,739 shares, increasing direct ownership by 13% to 23,100 units

      4 - Sientra, Inc. (0001551693) (Issuer)

      9/11/23 9:05:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction

      Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra's BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. ("Sientra" or the "Company") announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC ("Tiger") has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business. As consideration for the acquisition, Tiger will pay a cash consid

      4/2/24 6:30:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

      IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. The Company seeks to execute an expedited sale process. Sientra will utilize existing cash reserves and $22.5 million in new money d

      2/13/24 8:30:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Financials

    Live finance-specific insights

    See more
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook

      IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million in the prior year period. Third quarter results were adversely affected by overall softness in the market as well as more pronounced seasonal headwinds that led to a reduced number of augmentation and reconstru

      10/30/23 5:00:51 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Record Second Quarter Financial and Operational Results

      Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter tha

      8/10/23 4:03:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Sientra Announces Appointment of Alexander W. Casdin to Board of Directors

      IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023. "On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors," said Caro Van Hove, Executive Chair of Sientra. "With Kevin O'Boyle retiring from the Board after nearly a decade of exceptional

      6/20/23 8:35:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Appoints Two Medical Aesthetics Leaders to its Board of Directors

      SANTA BARBARA, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Dr. Irina Erenburg and Nori Ebersole to its Board of Directors effective July 16, 2021. "We are extremely pleased to welcome Irina and Nori to the Sientra Board," said Caroline Van Hove, Executive Chairwoman of Sientra. "Irina and Nori's deep respective experiences and competencies in building disruptive R&D engines and best-in-class organizations in Medical Aesthetics will significantly contribute to Sientra's high-growth strategy and our singular focus to be the number one

      7/19/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Announces Appointment of Chief Financial Officer

      SANTA BARBARA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Andy Schmidt has been appointed Chief Financial Officer (CFO) effective immediately. As a key member of Sientra's executive leadership team, Mr. Schmidt will lead the Company's financial operations. "We are extremely pleased to welcome a strong leader like Andy to the Sientra team. His experience with growth-oriented public companies will be invaluable as we work towards expanding our market share and advancing the art of plastic surgery," said Ron Menezes, President and Chief Executive Of

      7/12/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    SEC Filings

    See more
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/16/24 4:15:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/13/24 9:00:40 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      1/29/24 6:07:11 AM ET
      $SIEN
      Industrial Specialties
      Health Care